Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4111_Библиотеки_им_академика_М_И_Перельмана
.pdf
111
12. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent
venous Thromboembolism in relation to clinical and thrombophilic risk
factors: prospective cohort study. Lancet, 2003; 362: 523-526
13. Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism.
VASA , 2002; 31: 163-166
14. Wells PS, Anderson DR, Rodger M et al. Evaluation of d-dimer in the
diagnosis of suspected deep-vein thrombosis. N Engl J Med, 2003; 349:
1227-1235
15. Wells PS, Ginsberg JS? Anderson DR, et al. Use of a clinical model for
safe management of patients with suspected pulmonary embolism. Ann
Intern Med, 1998; 129: 997-1005
16. Wicki J, Perneger TV, Junod AF, Bounameaux H, Perrier A. Assessing
clinical probability of pulmonary embolism in the emergency ward. Arch
Intern Med, 2001; 161: 92-97
17. Stein PD, Hull RD, Patel KD, Olson RE. D-dimer for the exclusion of
acute venous thrombosis and pulmonary embolism. Ann Intern Med, 2004;
140: 589-602
18. Lensing AWA, Prandoni P, Brandjes D et al. Detection of deep-vein
thrombosis by real time B-mode ultrasonography. N Engl J Med, 1989;
320: 342-345
19. Elias A, Mallard L, Ellias M et al. A single complete ultrasound
investigation of the venous network for the diagnostic management of
patients with a clinically suspected first episode of deep venous
thrombosis of lower limbs. Thromb Haemost, 2003; 89: 221-227
20. Schellong SM, Schwarz T, Halbritter K et al. Complete compression
ultrasonography of the leg veins as a single test for the diagnosis of deep
vein thrombosis. Thromb Haemost, 2003; 89: 228-234
21. Hull R, Hirsh J, Sackett DL et al. Clinical validity of a negative venogram
in patients with clinically suspected venous thrombosis. Circulation, 1981;
64: 622-625
https://t.me/med1917
112
22. Lensing AW, Buller HR, Prandoni P et al. Contrast venography , the gold
standart for the diagnosis of deep-vein thrombosis: improvement in
observer agreement. Thromb Haemost, 1992; 67: 8-12
23. Hull RD, Raskob GE, Coates G, Panju AA. Clinically validity of a normal
perfusion lung scan in patients with suspected pulmonary embolism.
Chest, 1990; 97: 23-26
24. The PIOPED Investigators. Value of perfusion lung scan in the diagnosis
of pulmonary embolism: results of the prospective study of acute
pulmonary diagnosis. Am J Respir Crit Care Med, 1996; 154: 1387-1393
25. Ruehm SG, Zimny K, Debatin JF. Direct contrast-enhanced 3D MR
venography. Eur Radiol, 2001; 11: 102-112
26. Spritzer CE, Evans AC, Kay HH. Magnetic resonance imaging of deep
venous thrombosis in pregnant women with lower extremity edema.
Obstet Gynecol, 1995; 85: 603-607
27. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H.
Prognostic significance of right ventricular afterload stress detected by
echocardiography in patients with clinically suspected pulmonary
embolism. Heart, 1997; 77: 346-349
28. Fancher TL, White RH, Kravitz RL. Combined use of rapid d-dimer
testing and estimated of clinical probability in the diagnosis of deep vein
thrombosis: systematic review. Br Med J, 2004; 329: 821
29. van den Belt AG, Prins MH, Lensing AW et al. Fixed dose subcutaneous
low-molecular-weight heparin with unfractionated heparin for venous
thromboembolism. Cochrane Database Syst Rev, 2000; CD001100
30. Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaprin
for the initial treatment of symptomatic deep venous thrombosis. Ann
Intern Med, 2004; 140: 867-873
31. Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux
versus unfractionated heparin in the initial treatment of pulmonary
embolism. N Engl J Med, 2003; 348: 1695-1702
https://t.me/med1917
113
32. Arcasoy SM, Vachani A. Local and systemic thrombolitic Therapy for
acute venous Thromboembolism. Clin Chest Med, 2003: 24: 73-91
33. Urokinase Pulmonary Embolism Trial: phase 1 results—a cooperative
study. JAMA 1970; 214:2163–2172
34. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled
clinical trial of streptokinase and heparin in treatment of life-threatening
pulmonary embolism. BMJ, 1974; 1: 343-347
35. Ly B, Arnesen H, Erie H, et al. A controlled trial of streptokinase and
heparin in the treatment of major pulmonary embolism. Acta Med Scand,
1978; 203: 465-470
36. Marini C, Di Ricco G, Rossi G, et al. Fibrinolytic effects of urokinase and
heparin in acute pulmonary embolism: a randomized clinical trial.
Respiration, 1988; 54: 162-173
37. PIOPED Investigators. Tissue plasminogen activator for the treatment of
acute pulmonary embolism: a collaborative study by the PIOPED
Investigators. Chest, 1990; 97: 528-533
38. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus
dosage regimen of recombinant tissue plasminogen activator in patients
with acute pulmonary embolism. Chest, 1990; 98: 1473-1479
39. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase
combined with heparin versus heparin in the treatment of acute pulmonary
embolism: Plasminogen Activator Italian Multicenter Study 2. J Am Coll
Cardiol, 1992; 20: 520-526
40. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in
acute pulmonary embolism: randomised trial assessing right-ventricular
function and pulmonary perfusion. Lancet, 1993; 341: 507-511
41. Jerjes-Sanchez C, Ramirez-Rivera A, Garcia M de L, et al. Streptokinase
and heparin versus heparin alone in massive pulmonary embolism: a
randomized controlled trial. J Thromb Thrombolysis, 1995; 2: 227-229
https://t.me/med1917
114
42. Urokinase-Streptokinase Embolism Trial: phase 2 results—a cooperative
study. JAMA, 1974; 229:1606–1613
43. Goldhaber, SZ, Kessler, CM, Heit, J, et al Randomised controlled trial of
recombinant tissue plasminogen activator versus urokinase in the
treatment of acute pulmonary embolism. Lancet, 1988; 2: 293-298
44. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase
versus alteplase on total pulmonary resistance in acute massive pulmonary
embolism: a European multicenter double-blind trial. J Am Coll Cardiol,
1992; 19: 239-245
45. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type
plasminogen activator versus a novel dosing regimen of urokinase in acute
pulmonary embolism: a randomized controlled multicenter trial. J Am Coll
Cardiol, 1992; 20: 24-30
46. Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in
massive pulmonary embolism: a randomized trial assessing right heart
hemodynamics and pulmonary vascular obstruction. Eur Heart J, 1997; 18:
1141-1148
47. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-
hour regimen of streptokinase versus alteplase in acute massive pulmonary
embolism: immediate clinical and hemodynamic outcome and one-year
follow-up. J Am Coll Cardiol, 1998; 31: 1057-1063
48. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs
conventional alteplase infusion for pulmonary embolism thrombolysis: an
international multicenter randomized trial. Chest, 1994; 106: 718-724
49. Goldhaber SZ, Feldstein ML, Sors H Two trials of reduced bolus alteplase
in the treatment of pulmonary embolism: an overview. Chest, 1994; 106:
725-726
50. Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus vs 2-
h infusion of alteplase in acute massive pulmonary embolism: a
randomized controlled multicenter trial. Chest, 1994; 106: 712-717
https://t.me/med1917
115
51. Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms
with response to thrombolytic therapy in pulmonary embolism. Am J
Cardiol 1997; 80: 184-188
52. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest, February 2012; 141(2_suppl)
53. Konstantinides S, Geibel A, Heusel G, Heitich F, Kasper W. Heparin plus
alpeplase compared with heparin alone in patients with submassive
pulmonary embolism. N Engl J Med, 2002; 347: 1143-1450
54. Forster A, Wells P. Tissue plasminogen activator for the treatment of deep
venous thrombosis of lower extremity^ a systematic review. Chest, 2001;
119: 572-579
55. Verstraete M, Miller GAH, Bounameaux H, et al. Intravenous and
intrapulmonary recombinant tissue-type plasminogen activator in the
treatment of acute massive pulmonary embolism. Circulation 1988; 77:
353-360
56. Tapson VF, Gurbel PA, Witty LA, Pieper KS, Stack RS.
Pharmacomechanical thrombolysis of experimental pulmonary emboli.
Rapid low-dose intraembolic therapy. Chest, 1994; 106:1558-1562
57. Fava M, Loyola S, Flores P, Huete I. Mechanical fragmentation and
pharmacologic thrombolysis in massive pulmonary embolism. J Vasc
Interv Radiol, 1997; 8: 261-266
58. Baldwin ZK, Comerota AJ, Schwartz LB. Catheter-directed thrombolysis
for deep venous thrombosis. Vasc Endovascular Surg, 2004; 38:1-9
59. Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower
extremity deep venous thrombosis: report of national registry. Radiology,
1999; 211: 39-49
60. Streiff MB. Vena caval filters: a comprehensive review. Blood, 2000; 95:
3669-3677
https://t.me/med1917
116
61. Ashley DW, Mix JW, Christie B, Burton CG, Lochner FK, McCommon
GW, Matoy GC, Solis MM, Donner RS, Dalton ML, Tyson CS, Newman
WH. Removal of the OptEase retrievable vena cava filter is not feasible
after extended time periods because of filter protrusion through the vena
cava. J Trauma, 2005; 59: 847-852
62. Pellerin O, di Primio M, Sanchez O, Meyer G, Sapoval M. Successful
retrieval of 29 ALN inferior vena cava filters at a mean of 25.6 months
after placement. J Vasc Interv Radiol, 2013; 24: 284-288
63. Kinney TB. Primum non nocere. J Vasc Interv Radiol, 2012; 23: 1564-
1565.
64. Kuo WT, Robertson SW, Odegaard JI, Hofmann LV. Complex retrieval of
fractured, embedded, and penetrating inferior vena cava filters: a
prospective study with histologic and electron microscopic analysis. J
Vasc Interv Radiol, 2013; 24: 622-630
65. Gulba DC, Schmid C, Borst HG, Lichtlen P, Dietz R, Luft FC. Medical
compared with surgical treatment for massive pulmonary embolism.
Lancet, 1994; 343: 576-577
66. Yalamanchili K, Fleisher AG, Lehrman SG et al. Open pulmonary
embolectomy for treatment of major pulmonary embolism. Ann Thorac
Surg, 2004; 77: 819-823
67. Plate G, Eklof B, Norgren L, Ohlin P, Dahlstrom JA. Venous
thrombectomy for iliofemoral vein thrombosis: 10-year result of
prospective randomized study. Eur J Vasc Endovasc Surg, 1997; 14: 367-
374
68. Kniemeyer HW, Sandmann W, Schwindt C, Grabitz K, Torsello G,
Stuhmeier K. Thrombectomy with arteriovenous fistula for embolizing
deep venous thrombosis^ an alternative therapy for prevention of recurrent
pulmonary embollism. Clin Investig, 1993; 72: 40-45
https://t.me/med1917
117
69. Eklof B, Arfvidsson B, Kistner RL, Masuda EM. Indications for surgical
treatment of iliofemoral vein thrombosis. Hematol Oncol Clin North Am,
2000; 14: 471-482
70. Schellong SM, Schwarz T, Kropp J, Prescher Y, Beuthien-Baumann D,
Daniel WG. Bed rest in deep vein thrombosis and the incidence of
scintigraphic pulmonary embolism. Thromb Haemost, 1999; 82: 127-129
71. Ashwanden M, Labs KH, Engel H et al. Acute deep vein thrombosis: early
mobilization does not increase the frequency of pulmonary embolism.
Thromb Haemost, 2001; 85: 42-46
72. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous
thrombosis with intravenous unfractionated heparin administered in
hospital as compared with subcutaneous low-molecular-weight heparin
administered at home. N Engl J Med, 1996; 334: 682-687
73. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight
heparin administered primarily at home with unfractionated heparin
administered in hospital for proximal deep-vein thrombosis. N Engl J
Med, 1996; 334: 677-681
74. Schwarz T? Schmidt B, Hohlein U, Beyer J, Schroder HE, Schellong SM.
Eligbility for home treatment of deep venous thrombosis: prospective
study/ Br Med J, 2001; 322: 1212-1213
75. Beer JH, Burger M, Gretener S, Bernard-Bagattini S, Bounameaux H.
Outpatient treatment of pulmonary embolism is feasible and safe in a
substantial proportion of patients. J Thromb Haemost, 2003; 1:186-187
76. Pinede L, Ninet J, Duhaut P et al. Comparison of 3 and 6 months of oral
anticoagulant therapy after a first episode of proximal deep vein
thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of
therapy after isolated calf deep vein thrombosis. Circulation, 2001; 103:
2453-2460
https://t.me/med1917
118
77. Бокарев И.Н., Попова Л.В., Козлова Т.В. Тромбозы и
противотромботическая терапия в клинической практике. М.: 2009 –
512 с.
78. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorragic
complications of anticoagulant treatment. The Seventh ACCP Conference
on Antirhrombotic and Thrombolytic Therapy. Chest, 2004; 126:287S-
310S
79. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk
bleeding during anticoagulant treatment for venous thromboembolism.
Arch Intern Med, 1999; 159: 457-460
80. Prandoni P, Lensing AW, Bagatella P, Simiono P, Girolami A. Low rate of
warfarin-related major bleeding in patients with recurrent venous
thromboembolism [letter]. Thromb Haemost, 1999; 82: 158-159
81. Schulman S, Rhedin AS, Lindmarker P et al. A comparison of six weeks
with six months of oral anticoagulant therapy after a first episode of
venous thromboembolism. N Engl J Med, 1995; 332: 1661-1665
82. Schulman S, Granqvist S, Holmstrom M et al. The duration of oral
anticoagulant therapy after a second episode of venous thromboembolism.
N Engl J Med, 1997; 336: 393-398
83. Kearon C, Gent M, Hirsh J et al. A comparison of three months of
anticoagulation with extended anticoagulation for a first episode of
idiopathic venous thromboembolism. N Engl J med, 1999; 340: 901-907
84. Agnelli G, Prandoni P, Becattini C et al. Extended oral anticoagulant
therapy after a first episode of pulmonary embolism. Ann Intern Med,
2003; 139: 19-25
85. Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one
year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N
Engl J Med, 2001; 345: 165-169
86. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-
term treatment of symptomatic venous thromboembolism: meta-analysis
https://t.me/med1917
119
of the randomized comparisons with oral anticoagulants. J Thromb
Haemost, 2002; 1: 1906-1913
87. Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin
versus a coumarin for the prevention of recurrent venous
thromboembolism in patients with cancer. N Engl J med, 2003; 349: 146-
153
88. Douketis JD. Perioperative anticoagulant management in patients who are
receiving oral anticoagulant therapy^ a practical guide for clinicians.
Thromb Res, 2002; 108: 3-13
89. Hrebickova L, Nawarskas JJ, Anderson JR. Ximelagatran: a new oral
anticoagulant. Heart Dis (United States) , 2003; 5: 397-408
90. Shulman S, Wahlander K, Lundstrom T, et al. For the THRIVE III
Investigators. Secondary prevention of venous thromboembolism with the
oral direct thrombic inhibitor ximelagatran. N Engl J Med, 2003;
349:1713-1721
91. Huisman MV. Efficacy and safety of the oral direct thrombin inhibitor
ximelagatran for acute deep vein thrombosis with or without pulmonary
embolism [abstract OC003]. In: Program and abstracts for the XIX
Congress of the International Society on Thrombosis and Haemostasis.
Birmingham UK July 12-18, 2003.
92. J.-N. Fiessinger et al. Ximelagatran vs Low-Molecular-Weight Heparin
and Warfarin for the Treatment of Deep Vein Thrombosis. JAMA , 2005;
293:681-689
93. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller
HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH,
Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H,
Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for
symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;
363:2499-2510.
https://t.me/med1917
120
94. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW,
Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P,
Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL,
Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A.Oral
rivaroxaban for the treatment of symptomatic pulmonary embolism. N
Engl J Med. 2012; 366:1287-1297
95. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller
HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH,
Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H,
Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for
symptomatic venous thromboembolism. N Engl J Med, 2010; 363: 2499-
2510.
96. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H,
Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group.
Dabigatran versus warfarin in the treatment of acute venous
thromboembolism. N Engl J Med, 2009; 361: 2342-2352.
97. Schulman S, Kakkar AK, Schellong SM, et al. A randomized trial of
dabigatran versus warfarin in the treatment of acute venous
thromboembolism (RE-COVER II) Blood. 2011;118 Abstract 205.
98. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D,
Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ, RE-MEDY Trial
Investigators, RE-SONATE Trial Investigators. Extended use of
dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J
Med, 2013; 368: 709-718
99. Brandjes DPM, Buller HR, Heijboer H et al. Randomized trial of effect of
compression stockings in patients with symptomatic proximal-vein
thrombosis. Lancet, 1997; 349: 759-762
100. Decousus H, Epinat M, Guillot K, Quenet S, Boissier C, Tardy B.
Superficial vein thrombosis: risk factors, diagnosis and treatment. Curr
Opin Pulm Med, 2003; 9: 393-397
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана